The MPP is a public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatment. To date, we have secured licences for thirteen antiretrovirals, two hepatitis C direct-acting antivirals, one tuberculosis medicine and an HIV technology platform.

We have sublicensed to many product developers and generic manufacturers to develop and supply medicines in developing countries. Access our licence page.

MPP in Numbers

9
9 patent holders with MPP signed agreements
14.6
14.6 million patient-years through MPP’s generic partners from January 2012 to June 2017
20
20 generic manufacturers and product developers sublicensed from the MPP
17
17 products licensed to the MPP
130+
130+ ongoing pharmaceutical development projects
87% to 91%
87% to 91% of people living with HIV in developing countries covered by the MPP adult licences
92 to 131
92 to 131 countries covered by MPP adults licences
391
391 million dollars saved, from January 2012 to June 2017

KPMG calculated savings of $391 million and supply of 14.6 million patient-years of treatments through the MPP’s generic partners from January 2012 to June 2017

Access the report

HIV
HIV
Hepatitis C
Hepatitis C
Tuberculosis
Tuberculosis